EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

Pope welcomes cardiologists to Vatican City
Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”
Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
Early TAVR for asymptomatic severe AS cuts costs, improves outcomes
The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.
Pascal system from Edwards Lifesciences linked to key benefits after M-TEER, T-TEER
The interventional device, designed to perform both M-TEER and T-TEER, is at the center of two new studies published in EuroIntervention.
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

FFR-guided PCI linked to better 5-year outcomes than medical therapy

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

Edwards gains CE mark for first transcatheter tricuspid treatment

Edwards Lifesciences has received CE mark approval for its Cardioband Tricuspid Valve Reconstruction System, making it the first commercially available transcatheter therapy to treat tricuspid valve heart disease.

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

EuroPCR

Pope welcomes cardiologists to Vatican City

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

Pascal system from Edwards Lifesciences linked to key benefits after M-TEER, T-TEER

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards